Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

318.78
Delayed Data
As of Jul 31
 +1.78 / +0.56%
Today’s Change
290.85
Today|||52-Week Range
480.18
-6.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$75.2B

Company Description

Biogen, Inc. is a global biotechnology company, which develops markets and manufactures therapies for people living with neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded on November 12, 2003 and is headquartered in Cambridge, MA.

Contact Information

Biogen, Inc.
225 Binney Street
Cambridge Massachusetts 02142
P:(781) 464-2000
Investor Relations:
(781) 464-2442

Employees

Shareholders

Mutual fund holders56.38%
Other institutional36.78%
Individual stakeholders1.15%

Top Executives

George A. ScangosChief Executive Officer
Paul J. ClancyChief Financial Officer & Executive Vice President
Douglas E. WilliamsExecutive Vice President-Research & Development
Spyridon Artavanis-TsakonasChief Scientific Officer & Senior Vice President
Adriana KaraboutisExecutive VP-Technology & Business Solutions